|Oral, Sublingual, rectal|
|Elimination half-life||17 hours|
|Chemical and physical data|
|Molar mass||354.211 g·mol−1|
|3D model (JSmol)|
Pyrazolam (SH-I-04) is a benzodiazepine derivative originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s, and subsequently "rediscovered" and sold as a designer drug starting in 2012.
Pyrazolam has structural similarities to alprazolam and bromazepam. Unlike other benzodiazepines, pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine. It is most selective for the α2 and α3 subtypes of the GABAA receptor.